This phenomenon likely explains why ERBB2‐amplified ILBC behaves in a more similar clinical manner to ERBB2‐amplified NST carcinomas as has been already postulated in sparse previous literature sources on NST breast carcinomas [3, 4, 5, 6, 29]. This evidence concerns the gene ERBB2 and breast carcinoma.